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Introduction and aims:  The branched-chain aminotransferase (BCAT) enzymes are 
important in the regulation of brain L-glutamate. A unique function of these 
aminotransferases is their regulation by the redox environment, where our group have 
shown their function as oxidoreductases, and their ability to refold misfolded proteins in 
particular when S-glutathionylated. Our group recently showed a significant increase in 
the level of these proteins in Alzheimer’s disease brain. An increase in BCAT activity 
could generate excess L-glutamate, contributing to the excitotoxic environment observed 
under pathogenic conditions.  Alternatively, we hypothesize that if this protein is modified 
in response to cellular stress, it may play a more prominent role in regulating redox status 
or protein folding. To address these questions this project focussed on the design of 
chemical inhibitors and knock-down models together with a co-culture model of the 
human cerebrovasculature and specifically targeted key metabolic and redox pathways. 
Methods: Several chemical inhibitors based on 4-Benzyloxyphenylacetic acid were 
identified using the DockBlaster and Schrödinger software suites, synthesized and 
structurally verified using proton nuclear magnetic resonance (NMR) spectroscopy.  The 
functional impact and specificity of these inhibitors was assessed using the BCAT 
radiolabelled assay and a coupled-enzyme assay.  In tandem, siRNA was used to knock-
down both isoforms in SH-SY5Y cells, and validated using western blot analysis and RT-
PCR.  The impact of BCATm knock-down on the expression of redox proteins, in addition 
to selected metabolic proteins, was assessed by western blot analysis.  Functional redox 
assays, including glutathione concentration and metabolic activity, were also used to 
investigate the impact of human BCAT (hBCAT) expression in neuronal cells.  Finally, a 
model of the blood-brain barrier (BBB) was developed and validated for studies into the 
role of mitochondrial hBCAT (hBCATm) in brain microvasculature. 
Results:  For the first time we have identified a family of chemical inhibitors of hBCATm.  
In particular, benzofenac has a two-fold greater enzyme affinity for hBCATm (Ki=43 µM) 
than cytosolic hBCAT (hBCATc) (Ki=93 µM) and a four-fold greater inhibition relative to 
alanine transaminase (ALT; Ki=167 µM). These inhibitors will require further optimisation 
but have potential as tools to assess the cellular function of hBCAT.  In separate studies, 
knock-down of hBCATm in SH-SY5Y neuronal cells demonstrated that hBCATm 
expression has an impact on the metabolic and redox status of the cell.  In particular, 
knock-down caused a >70% decrease in glutaredoxin (GRx), thioredoxin (TRx), 
branched-chain α-keto acid dehydrogenase α-subunit (BCKDHA), and AU-rich binding 
homolog of enoyl-CoA hydratase (AUH) expression.  Interestingly, this effect was 
attenuated when cells were treated with L-leucine, indicating that these mechanisms may 
be regulated by a metabolic signal.  L-glutamate treatment was also found to significantly 
increase hBCATm expression, but decreased glutamate dehydrogenase (GDH) 
expression, except in cells overexpressing hBCATm, suggesting a metabolic synergy 
between the two enzymes.  Finally, total glutathione concentration was significantly 
decreased on hBCATm knock-down, while sensitivity to L-glutamate toxicity was 
significantly increased.   
Discussion:  Results from this work have significantly contributed to the design of 
cellular models, which can be used to further investigate the role of BCAT in metabolic 
and redox metabolism.  A model of the human blood-brain barrier, developed in this 
thesis, will also contribute to evaluating the endothelial role of hBCATm. The initial impact 
of limiting BCAT expression is both a decrease in the expression of key metabolic 
proteins and also the cellular reductants.  Together this had an impact on cell survival.  
Knowledge of these pathways and their regulation will be important to our understanding, 
of not only the regulation of brain L-glutamate, but also the role of BCAT in protein folding 
and cellular redox status.  These factors are fundamentally important to development of 
neurodegenerative conditions but also in tumour development such as gliomas. 
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